Signos has completed a successful $20 million Series B fundraising round. This metabolic health platform combines a novel AI engine with a continuous glucose monitor (CGM) to provide real-time data and suggestions for healthy weight control. Cheyenne Ventures and GV (Google Ventures) co-led the round with contributions from Samsung and Dexcom Ventures. It will allow Signos to grow its staff, widen its platform, and conduct further metabolic health studies.
The goal of Signos is to solve the obesity and metabolic health issue that is presently plaguing Americans. By 2050, it is expected that 1 billion individuals will develop diabetes, with more than 96 million Americans already having prediabetes. According to the firm, early diagnosis and lifestyle adjustments are more important than ever.
Users of the Signos app may track their food consumption and exercise habits, which helps the AI platform understand how a person’s metabolism reacts to various diets and exercise routines. This data then offers tailored, data-driven suggestions based on a person’s metabolic profile.
Sharam Fouladgar-Mercer, CEO of Signos, discussed the company’s goals in an interview with TechCrunch. Fouladgar-Mercer has battled his weight since he was a youngster. Therefore, he knows the difficulties of losing weight and the ineffectiveness of a diet that works for everyone. His experiences motivated him to use CGM technology to make glucose insight available to a larger community, including people with type 2 diabetes.
“With the help of this fresh investment round, we will be able to grow our platform and core staff and conduct further research on metabolic health. According to Fouladgar-Mercer, the cash will enable us to reach more potential members.
However, the corporation claims that problems still exist. The company’s main areas of concentration are finding qualified personnel and making the Signos platform broadly accessible, especially given the relatively expensive cost of CGM technology. Fouladgar-Mercer expresses optimism in these difficulties, saying, “We’re excited to continue to build something that can change lives for the better.”
Recently, there has been a lot of exciting activity in this area. Similar to Scanbo, which I reported almost two years ago, HME Square demonstrated photo-acoustics at TechCrunch Disrupt this year as a method of testing blood glucose without having to pierce the skin with a filament. Several additional firms, including Limbo, are active in this market. Ultimately, consumers who want to check their metabolic health closely will benefit from the rivalry and race for innovation.
I wondered if the CEO had changed his behavior due to his work on Signos. Both yes and no. I enjoy making sourdough bread (yes, you can eat bread if you’re following a diet that promotes glucose uptake),” Fouladgar-Mercer remarked. But when I do bake, I try to time my bread consumption so that I can take a little walk to help reduce the glucose surge as needed. Finding a healthy diet and workout routine that works for your metabolism is more important than eliminating all carbohydrates.
Signos asserts that with this fresh infusion of cash, it is in a strong position to carry on its ground-breaking work in metabolic health and weight control and offer a much-needed remedy to a worsening health problem.
